Josh Brumm, previously CEO of Dyne Therapeutics, appointed as General Partner at Forbion Brumm to be located at Forbion's new offices in the heart of the Boston (MA) biotech hub, supporting Forbion's long-standing activities in the US and Canadian markets NAARDEN, The Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- Forbion, a leading global life sciences venture capital firm with deep expertise in Europe, has hired former Dyne Therapeutics ("Dyne") President and CEO Josh Brumm as a General Partner and is opening an office in Boston, Massachusetts. Josh brings considerable experience in building and leading biotech businesses. He joins Forbion from Dyne, a  ̴ $3.5 billion Forbion portfolio company. He led Dyne through its initial public offering on Nasdaq in 2020, and advanced two rare muscle disease programs into clinical trials. Prior to Dyne, he held leadership roles at several other biotechs, including Proteolix, Pharmacyclics and ZELTIQ Aesthetics, all of which were acquired by large pharmaceutical companies. In his new role, Josh's focus will be on bringing his strategic insights and network to source new opportunities across North America and Europe and support existing ...